| Code | Display | Definition |
| DE109 |
Birth dose |
Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen. |
| DE103 |
Type of dose |
The type of dose in a series that the client received |
| DE104 |
Primary series |
Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose. |
| DE105 |
Dose 0 |
Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series. |
| DE106 |
Supplementary dose |
Indicates that the client received a supplementary dose of a product/antigen |
| DE107 |
Booster dose |
Indicates that the client received booster dose of a product/antigen |
| DE8 |
Completed the primary vaccination series |
Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen. |
| DE102 |
Completed the booster series |
Indicates if the client has completed the booster series of a product/antigen |
| DE81 |
Date when primary vaccination series was completed |
The date when the client completed the primary vaccination series (per product/antigen) |
| DE10 |
HIV status |
The current human immunodeficiency virus (HIV) status of the client |
| DE11 |
HIV-positive |
The client is known to be HIV positive |
| DE12 |
HIV-negative |
The client is known to be HIV negative |
| DE13 |
Unknown |
The client's HIV status is unknown |
| DE15 |
Preterm birth |
The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks |
| DE16 |
Immunocompromised |
The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases |
| DE17 |
Currently on ART |
The client is currently receiving antiretroviral therapy (ART) |
| DE84 |
Type of TB infection test performed |
The type of TB infection test performed |
| DE85 |
IGRA |
Interferon-gamma release assay (IGRA) |
| DE86 |
TST |
Tuberculin skin test (TST) |
| DE87 |
TB infection test result |
Records the result of the TB infection test |
| DE88 |
Positive |
Test result was positive |
| DE89 |
Negative |
Test result was negative |
| DE93 |
Immunologically stable |
The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines |
| DE94 |
Clinically well |
The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging |
| DE29 |
Birth weight in grams |
Represents the client's birth weight value measures in grams |
| DE35 |
Type of polio dose |
The type of the polio vaccine dose administered to the client |
| DE36 |
IPV |
Inactivated poliovirus vaccine (IPV) |
| DE37 |
bOPV |
Bivalent oral poliovirus vaccine (bOPV) |
| DE92 |
Severely immunosuppressed |
The client is known to be severely immunosuppressed |
| DE49 |
ART start date |
The date on which the client started or restarted antiretroviral therapy (ART) |
| DE96 |
High risk of pneumococcal infection |
The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease) |
| DE52 |
Type of JE dose |
The type of Japanese encephalitis (JE) vaccine dose administered to the client |
| DE53 |
Inactivated Vero cell-derived vaccine |
Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type |
| DE54 |
Live attenuated vaccine |
Live attenuated Japanese encephalitis (JE) vaccine type |
| DE55 |
Live recombinant vaccine |
Live recombinant Japanese encephalitis (JE) vaccine type |
| DE56 |
Type of TBE dose |
The type of tick-borne encephalitis (TBE) vaccine dose administered |
| DE57 |
FSME-Immun |
FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE) |
| DE58 |
Encepur |
Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE) |
| DE59 |
TBE-Moscow |
TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE) |
| DE60 |
EnceVir |
EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE) |
| DE61 |
Type of typhoid dose |
The type of typhoid vaccine dose administered to the client |
| DE62 |
Typbar-TCV |
Typbar-TCV vaccine |
| DE63 |
ViPS |
Vi polysaccharide (ViPS) vaccine |
| DE64 |
Ty21a |
Ty21a vaccine |
| DE65 |
Type of cholera dose |
The type of cholera vaccine dose administered to the client |
| DE66 |
WC vaccine |
Killed whole cell (WC) only cholera vaccine |
| DE67 |
WC-rBS vaccine |
Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC) |
| DE68 |
Type of meningococcal dose |
The type of meningococcal vaccine dose administered to the client |
| DE69 |
MenA conjugate vaccine (5µg) |
Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine |
| DE70 |
Monovalent MenC conjugate |
Monovalent MenC conjugate vaccine |
| DE71 |
Quadrivalent conjugate |
Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines |
| DE97 |
Polysaccharide vaccine |
Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines |
| DE72 |
Age in months when client received first meningococcal dose |
The age in months when client received their first meningococcal dose |
| DE73 |
Type of hepatitis A dose |
The type of hepatitis A vaccine dose administered to the client |
| DE74 |
Live attenuated hepatitis A vaccine |
Live attenuated hepatitis A vaccine |
| DE75 |
Inactivated hepatitis A vaccine |
Inactivated hepatitis A vaccine |
| DE99 |
Type of hepatitis B dose |
The type of hepatitis B vaccine dose administered to the client |
| DE100 |
Hepatitis B monovalent vaccine |
Hepatitis B monovalent vaccine |
| DE101 |
Hepatitis B combination vaccine |
Hepatitis B combination vaccine |
| DE76 |
VNA level |
Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV) |
| DE98 |
Risk of occupational exposure to rabies virus |
Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies. |
| DE77 |
Dengue serostatus |
Indicates the result of a serological test determining whether the client has antibodies against the dengue virus |
| DE110 |
Positive |
The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination |
| DE111 |
Negative |
The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus |
| DE112 |
Unknown |
The client's dengue serostatus is unknown |
